We are headquartered in the United States, with three global centers in Pittsburgh, Pennsylvania, U.S., Shanghai, China, and Hyderabad, India. We operate approximately 40 manufacturing facilities, which produce complex dosage forms, injectables, oral solid doses and active pharmaceutical ingredients. And we maintain an industry-leading pipeline, composed of numerous complex generics and global key brands.

As we work to fully transition to the Viatris brand commercially and operationally around the world, you may continue to see both the Mylan and Upjohn names in certain markets. Throughout this process, our priority remains serving patients by finding innovative solutions to meet their evolving healthcare needs.